LUND,
Sweden, Jan. 17, 2023 /PRNewswire/ -- Immunovia
(NASDAQ Stockholm: IMMNOV), the diagnostics company that has
launched the world's first blood test dedicated to the early
detection of pancreatic cancer, today announced that it has
appointed Lara E. Sucheston-Campbell as the Head of Clinical and
Medical Affairs effective February 1,
2023.
Lara joins Immunovia from Roche Molecular Systems, where she
served as Global Director of Clinical Development in Oncology and
Genetics. Prior to joining Roche, she spent over 13 years in
academia, most recently as a tenured Associate Professor at The
Ohio State University. Her lab focused
on the contribution of genomics to cancer susceptibility and
survival following diagnosis.
Lara brings expertise in designing, implementing, analyzing, and
leading large-scale international clinical, biomarker, genomic and
epidemiologic studies resulting in national and international
scientific presentations and over 130 peer-reviewed publications.
Her academic research was funded by the National Institutes of
Health and Department of Defense. She has extensive experience in
leading clinical science teams and collaborating with key opinion
leaders. Lara holds a PhD in Genetic and Molecular Epidemiology
from Case Western Reserve University,
an MS in Genetic Counseling from The Ohio
State University as well as degrees in engineering and
economics.
"We are thrilled to welcome Lara to Immunovia. Her broad
expertise in study design and execution as well as working with key
opinion leaders will help us to bolster the clinical evidence
supporting the IMMray™ PanCan-d test, drive further clinician
adoption and secure payer coverage," said Philipp Mathieu, CEO and President of
Immunovia.
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on NASDAQ Stockholm. For
more information, please visit www.immunovia.com
CONTACT:
Philipp Mathieu,
Group CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
The following files are available for download:
https://mb.cision.com/Main/13121/3698655/1784046.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/immunovia-appoints-lara-e-sucheston-campbell-as-head-of-clinical-and-medical-affairs-to-accelerate-commercial-strategy-of-immray-pancan-d-test-in-the-us-market-301723097.html
SOURCE Immunovia AB